{"schema":1,"revision":"f4c38a39755c3a1a1be7b75ca706874d279dbd1b8599ec0bdef4190c92239ba1","as_of":"2026-11-01","rows":[{"交易ID":"ASIA-2026-9967add55f34","公告日期":"2026-10-29","授權方_中文名":"GC綠十字；韓美藥品","授權方_英文名":"GC Biopharma Corp.; Hanmi Pharm Co., Ltd.","授權方_國家":"韓國","授權方_上市代號":"KRX:006280 (GC Biopharma Corp.); KRX:128940 (Hanmi Pharm Co., Ltd.)","被授權方_英文名":"BioMarin Pharmaceutical Inc.","被授權方_國家":"美國","資產名稱與代號":"HM15421 / GC1134A (LA-GLA)","藥物類型":"長效皮下注射重組酵素替代療法","標的或機制":"Alpha-galactosidase A replacement (Fabry disease)","最高開發階段_公告當時":"Phase 1/2","授權地區範圍":"Worldwide excluding Korea","交易類型":"Exclusive license","首付款_美元":"70000000","近期里程碑_美元":"","交易總額上限_美元":"475000000","權利金描述":"Tiered net-sales royalties; rates undisclosed","來源網址1":"https://investors.biomarin.com/news/news-details/2026/BioMarin-Enters-Into-Exclusive-Worldwide-License-Agreement-With-GC-Biopharma-and-Hanmi-Pharm-for-Investigational-Next-Generation-Enzyme-Replacement-Therapy-Adding-a-Second-Potential-Treatment-for-Fabry-Disease/default.aspx","來源網址2":"https://www.hanmi.co.kr/about/news-media/press/detail-5182.hm","來源日期":"2026-10-29","查核時間":"2026-11-01T18:28:49+08:00","備註":"共同授權同一協議僅一筆。US$70m首付＋最高US$405m開發/商業里程碑＝US$475m，不是各授權方各得此額。無近期里程碑時程。採美國10/29首發，韓國原稿10/30。BioMarin原稿明列總部San Rafael, California。"},{"交易ID":"ASIA-2026-ddccf0af28dd","公告日期":"2026-10-19","授權方_中文名":"劑泰科技（北京）股份有限公司","授權方_英文名":"METiS TechBio","授權方_國家":"中國","授權方_上市代號":"7666.HK","被授權方_英文名":"Eli Lilly and Company","被授權方_國家":"美國","資產名稱與代號":"組織特異性LNP遞送合作；AiLNP平台（未披露具名藥物）","藥物類型":"脂質奈米顆粒藥物遞送平台","標的或機制":"","最高開發階段_公告當時":"探索研究／發現階段（平台合作）","授權地區範圍":"","交易類型":"藥物遞送平台研究合作","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"合作產品年度淨銷售額的個位數百分比分級權利金","來源網址1":"https://metistechbio.com/en/qyxw/253.html","來源網址2":"https://www.metistechbio.com/qyxw/303.html","來源日期":"2026-10-19","查核時間":"2026-11-01T18:28:49+08:00","備註":"原稿首付僅稱低兩位數百萬美元，中文稱逾千萬美元，未給精確值；另有最高約11億美元開發、監管及商業里程碑。11億不是包含首付的精確總額上限，故兩數值欄留空。未披露個別藥物、靶點或地域，不套用公司其他產品的臨床期別。中英文稿為同一協議，只計一筆。"},{"交易ID":"ASIA-2026-3a7f3b896aa1","公告日期":"2026-10-19","授權方_中文名":"翰森製藥集團有限公司","授權方_英文名":"Hansoh Pharmaceutical Group Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"03692.HK","被授權方_英文名":"Roche","被授權方_國家":"瑞士","資產名稱與代號":"兩項未具名臨床前ADC及以羅氏提出靶點開發的多項ADC計畫","藥物類型":"抗體藥物複合體（ADC）及ADC技術平台","標的或機制":"","最高開發階段_公告當時":"臨床前（兩項已納入計畫）；其他平台衍生計畫未披露個別階段","授權地區範圍":"全球，不含中國大陸、香港、澳門及台灣；翰森保留上述地區權利","交易類型":"多計畫合作與獨家權利授權","首付款_美元":"400000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"未來產品銷售的分級權利金，比例未披露","來源網址1":"https://www.hspharm.com/news/news-detail-513518.htm","來源網址2":"https://www.hansoh.cn/news/news-detail-514090.htm","來源日期":"2026-10-19","查核時間":"2026-11-01T18:28:49+08:00","備註":"另有首周年固定付款1.1億美元，不能當近期里程碑；潛在里程碑原文是超過150億美元，沒有給精確上限，因此總額上限留空。翰森負責至全球Ia期完成是未來分工，非公告時已到Ia期。翰森可選最多兩項計畫分擔境外開發、換取額外美國經濟利益；同一協議只計一筆。"},{"交易ID":"ASIA-2026-d387fcf903d3","公告日期":"2026-10-13","授權方_中文名":"武漢海特生物製藥股份有限公司","授權方_英文名":"Wuhan Hiteck Biological Pharma Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"300683.SZ","被授權方_英文名":"Visara, Inc.","被授權方_國家":"美國","資產名稱與代號":"HT006.2.2滴眼液／VIS-102","藥物類型":"修飾型重組人神經生長因子（rhNGF）眼用生物製劑","標的或機制":"TrkA；p75NTR","最高開發階段_公告當時":"Phase 1b（已披露中國受試者資料，擴展研究繼續）","授權地區範圍":"全球，不含大中華區","交易類型":"獨家藥物開發及商業化授權","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"授權區域年度淨銷售額的一定比例；受讓方原稿稱分級權利金，未披露比例","來源網址1":"https://static.cninfo.com.cn/finalpage/2026-10-13/1225602615.PDF","來源網址2":"https://www.globenewswire.com/news-release/2026/10/13/3379526/0/en/visara-expands-ophthalmology-pipeline-with-exclusive-license-for-investigational-nerve-growth-factor-therapy-for-neurotrophic-keratitis.html","來源日期":"2026-10-13","查核時間":"2026-11-01T18:28:49+08:00","備註":"公告分別披露700萬美元首付與近期里程碑合計，以及最高1.04億美元其他開發、監管及商業里程碑；未明列整體總額，不自行相加，total_cap留空。700萬未分拆，首付及近期各欄皆留空。CNINFO確認實際許可雙方、Visara為美國特拉華州公司及靶點；英文公司原稿補公告當時Phase1b。公司原稿以Rockville發稿，母公司官網列Rockville辦公地址；Visara獨立總部街址未單獨披露，不把母公司香港或上海據點當受讓方總部。"},{"交易ID":"ASIA-2026-74ec25a444e7","公告日期":"2026-10-09","授權方_中文名":"三迭紀；三迭紀（上海）","授權方_英文名":"Triastek, Inc.; Triastek (Shanghai) Limited","授權方_國家":"中國","授權方_上市代號":"","被授權方_英文名":"Janssen Pharmaceutica NV (Johnson & Johnson)","被授權方_國家":"比利時","資產名稱與代號":"MED&SSE三維藥物列印及3DμS-OM口服大分子遞送平台合作（未披露具名藥物）","藥物類型":"口服胜肽及其他治療模式的藥物遞送平台","標的或機制":"","最高開發階段_公告當時":"","授權地區範圍":"","交易類型":"藥物開發合作與授權；另附股權投資","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"","來源網址1":"https://www.triastek.com/detail/44.html","來源網址2":"https://www.jnj.com/innovativemedicine/emea/privacy-policy","來源日期":"2026-10-09","查核時間":"2026-11-01T18:28:49+08:00","備註":"原稿明定為Collaboration and License Agreement，並列中國上海全資子公司共同簽約；不是單獨CDMO供應。公告註明法律實體為Janssen Pharmaceutica NV，採比利時實體的國家而非把美國J&J集團所在地混寫。JJDC股權投資為另一部分，未披露金額，不填入藥物授權首付或總額。所涉候選藥及期別、靶點、地域及經濟條款均未公布。"},{"交易ID":"ASIA-2026-3c4a04240cae","公告日期":"2026-10-08","授權方_中文名":"杭州迪拓生物醫藥有限公司","授權方_英文名":"Defand Therapeutics","授權方_國家":"中國","授權方_上市代號":"","被授權方_英文名":"Roche","被授權方_國家":"瑞士","資產名稱與代號":"多靶點分子膠降解劑研究與授權計畫（未披露具名藥物）","藥物類型":"小分子分子膠降解劑（MGD）平台","標的或機制":"","最高開發階段_公告當時":"","授權地區範圍":"全球獨家商業化權利","交易類型":"多靶點研究合作及藥物授權","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"","來源網址1":"https://junhe.com/deals/1049","來源網址2":"https://www.defandtx.com/","來源日期":"2026-10-08","查核時間":"2026-11-01T18:28:49+08:00","備註":"交易全文一手證據是受迪拓委託、實際審閱修改並談判協議的君合承辦公告，非公司或交易所原稿；公司域名可由搜尋索引實讀平台及杭州地址，但直接開啟無可讀正文，未取得其交易原稿。按主線標準金額、權利金及公告當時stage均留空，不採媒體匿名來源的近10億美元估計。君合明載先共同發現藥物、達指定研究節點後由羅氏承接臨床前及臨床開發；不套用迪拓其他管線期別。此筆應保留來源等級標記供主線驗收。"},{"交易ID":"ASIA-2026-811eb08df2ca","公告日期":"2026-10-07","授權方_中文名":"江蘇亞虹醫藥科技股份有限公司","授權方_英文名":"Asieris Pharmaceuticals","授權方_國家":"中國","授權方_上市代號":"688176.SH","被授權方_英文名":"Theramex","被授權方_國家":"英國","資產名稱與代號":"CEVIRA／APL-1702（hexaminolevulinate hydrochloride光動力治療系統）","藥物類型":"藥械組合之光動力治療","標的或機制":"","最高開發階段_公告當時":"中國已核准（2026年3月）；歐洲等授權區域仍在研","授權地區範圍":"全部歐洲國家、澳大利亞、紐西蘭及土耳其；亞虹保留其他地區","交易類型":"附條件獨家藥物產品授權","首付款_美元":"15000000","近期里程碑_美元":"11000000","交易總額上限_美元":"","權利金描述":"分級銷售權利金，比例未披露","來源網址1":"https://www.theramex.com/news/theramex-enters-an-exclusive-licensing-agreement-with-asieris-for-cevira/","來源網址2":"https://www.asieris.cn/cn/contact.html","來源日期":"2026-10-07","查核時間":"2026-11-01T18:28:49+08:00","備註":"首付1500萬美元附供應協議、廠址稽核、與上游協議銜接及歐盟器械臨床價值評估釐清等條件，不能當作公告時已收現金。另1100萬為近期監管里程碑；總交易值只稱超過2.5億美元，未給精確最高上限，故total_cap留空。產品含藥物及裝置，屬藥械組合授權，非純醫材交易；未把中國核准等同歐洲核准。"},{"交易ID":"ASIA-2026-9fe90cea4152","公告日期":"2026-10-02","授權方_中文名":"艾博生物（蘇州艾博生物科技有限公司）","授權方_英文名":"Abogen Biosciences","授權方_國家":"中國","授權方_上市代號":"","被授權方_英文名":"Novartis","被授權方_國家":"瑞士","資產名稱與代號":"ABO2203及其他RNA平台衍生計畫的獨家選擇權","藥物類型":"mRNA編碼T細胞銜接器；RNA治療平台","標的或機制":"CD19 × CD3（ABO2203）；其他選擇權計畫未披露","最高開發階段_公告當時":"已進入臨床評估（原稿未列ABO2203期別）","授權地區範圍":"全球獨家ABO2203授權；其他計畫為獨家授權選擇權","交易類型":"藥物授權及多計畫獨家選擇權","首付款_美元":"575000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"未來產品銷售之潛在權利金，比例未披露","來源網址1":"https://www.prnewswire.com/news-releases/abogen-announces-licensing-and-option-agreement-with-novartis-to-advance-mrna-encoded-t-cell-engager-and-other-potential-rna-programs-302896950.html","來源網址2":"https://www.abogenbio.com/news/company/news2026/277.html","來源日期":"2026-10-02","查核時間":"2026-11-01T18:28:49+08:00","備註":"原稿披露5.75億美元首付，以及最高約72億美元開發、監管及商業里程碑；未直接披露整體總額，不自行相加，total_cap留空。里程碑須全部計畫選擇權均行使及達成各項條件，未含權利金，不能當作ABO2203單品保證總價。交易仍需慣常交割及監管條件。原稿說ABO2203已進臨床評估；同稿Phase3是另一項帶狀疱疹疫苗ABO1108，不可移植。公司新聞頁直接讀取逾時，已改用公司提供的PRNewswire完整原稿交叉核對官網索引，非媒體編寫稿。"},{"交易ID":"ASIA-2026-98797eb63f68","公告日期":"2026-09-29","授權方_中文名":"江蘇恒瑞醫藥股份有限公司","授權方_英文名":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"600276.SH; 01276.HK","被授權方_英文名":"Novo Nordisk A/S","被授權方_國家":"丹麥","資產名稱與代號":"HRS-1596","藥物類型":"口服雙受體致效劑","標的或機制":"GLP-1R / GIPR","最高開發階段_公告當時":"Phase I-ready；中國已准許啟動一期，未稱已收案","授權地區範圍":"全球，排除中國大陸、香港、澳門及台灣","交易類型":"獨家藥物權利授權","首付款_美元":"300000000","近期里程碑_美元":"","交易總額上限_美元":"2600000000","權利金描述":"授權區域淨銷售額權利金；費率未披露","來源網址1":"https://www.hengrui.com/en/media/detail-1042.html","來源網址2":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0929/2026092900263.pdf","來源日期":"2026-09-29","查核時間":"2026-11-01T18:28:49+08:00","備註":"總額上限包含首付；另最高USD 2.3bn條件式開發、監管及商業里程碑，非近期里程碑。公告時仍待HSR及其他交割條件，預計2026第四季交割。HKEX列明實際雙方及Novo丹麥總部；恒瑞為PRC設立公司。"},{"交易ID":"ASIA-2026-c654897a9d51","公告日期":"2026-09-28","授權方_中文名":"思璞銳","授權方_英文名":"SciBrunch Therapeutics Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"","被授權方_英文名":"Merck & Co., Inc.","被授權方_國家":"美國","資產名稱與代號":"SPR2015","藥物類型":"口服小分子分子膠抑制劑","標的或機制":"KRAS G12D (ON)","最高開發階段_公告當時":"臨床前","授權地區範圍":"全球","交易類型":"獨家藥物權利授權","首付款_美元":"400000000","近期里程碑_美元":"","交易總額上限_美元":"2130000000","權利金描述":"","來源網址1":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-for-spr2015-an-investigational-oral-kras-g12d-on-inhibitor/","來源網址2":"https://www.merck.com/contact-us/","來源日期":"2026-09-28","查核時間":"2026-11-01T18:28:49+08:00","備註":"原稿稱已交割；總額含首付與條件式里程碑，未拆近期付款或披露權利金。資產仍臨床前；公司整體clinical-stage不能代替資產期別。授權方上海總部；對手是美國Merck（海外稱MSD），不是德國Merck。中文僅採官網品牌名，不擴寫未核法律全名。"},{"交易ID":"ASIA-2026-7d697ad8879d","公告日期":"2026-09-28","授權方_中文名":"田邊製藥","授權方_英文名":"Tanabe Pharma Corporation","授權方_國家":"日本","授權方_上市代號":"","被授權方_英文名":"Tolerance Bio, Inc.","被授權方_國家":"美國","資產名稱與代號":"MT-2990 / TLB-33","藥物類型":"全人源 IgG1 單株抗體","標的或機制":"IL-33","最高開發階段_公告當時":"臨床階段；已完成/進行過五項臨床研究，Phase 2 預計 2027 年啟動","授權地區範圍":"全球開發權；日本以外獨家商業化權，日本商業化權由 Tanabe 保留","交易類型":"獨家藥物授權","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"按淨銷售額計算的分級權利金；級距未披露","來源網址1":"https://www.tanabe-pharma.com/en/news/rel_260928_2/main/0/link/e_rel_260928_2.pdf","來源網址2":"https://www.tolerancebio.com/recent-news/tolerance-bio-licenses-clinical-stage-anti-il-33-monoclonal-antibody-from-tanabe-pharma-to-expand-thymus-focused-clinical-pipeline","來源日期":"2026-09-28","查核時間":"2026-11-01T18:28:49+08:00","備註":"一手公告明列 Tanabe 大阪、Tolerance Bio 費城總部。約 USD 560,000,000 僅是潛在開發與銷售里程碑上限，另有股權對價及權利金；現金首付、近期里程碑拆分及全部對價上限未披露，故數值欄留空。Phase 2 是未來計畫，不能記為已啟動。授權方未填歷史上市代碼。"},{"交易ID":"ASIA-2026-46695c00a586","公告日期":"2026-09-24","授權方_中文名":"諾誠健華醫藥有限公司","授權方_英文名":"InnoCare Pharma Limited","授權方_國家":"中國","授權方_上市代號":"9969.HK; 688428.SH","被授權方_英文名":"Eli Lilly and Company","被授權方_國家":"美國","資產名稱與代號":"最多5個未披露靶點之藥物發現計畫","藥物類型":"藥物發現平台合作；分子形式未披露","標的或機制":"","最高開發階段_公告當時":"藥物發現","授權地區範圍":"","交易類型":"策略研究合作及授權","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"年度產品淨銷售額之個位數分級權利金","來源網址1":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0924/2026092400197.pdf","來源網址2":"https://www.lilly.com/about/key-facts","來源日期":"2026-09-24","查核時間":"2026-11-01T18:28:49+08:00","備註":"USD 100m是首付及近期付款合計上限，未分拆，兩欄均留空；另最高約USD 3.25bn開發及商業里程碑，不自行加總為官方總交易額。靶點、分子及地域未披露。雖於Cayman設立，2026中報p8明列主營總部北京，按亞洲營運總部納入。"},{"交易ID":"ASIA-2026-002b53a4c537","公告日期":"2026-09-22","授權方_中文名":"蘇州博銳創合醫藥有限公司","授權方_英文名":"Boomray Pharmaceuticals Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"","被授權方_英文名":"Novartis Pharma AG","被授權方_國家":"瑞士","資產名稱與代號":"未披露代號之放射性配體治療資產","藥物類型":"放射性配體治療（RLT）","標的或機制":"","最高開發階段_公告當時":"臨床前","授權地區範圍":"全球","交易類型":"獨家藥物權利授權","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"900000000","權利金描述":"未來全球淨銷售額權利金；費率未披露","來源網址1":"https://en.prnasia.com/releases/global/boomray-enters-exclusive-global-license-agreement-with-novartis-for-a-novel-radioligand-therapy-asset-548932.shtml","來源網址2":"https://www.novartis.com/about/locations","來源日期":"2026-09-22","查核時間":"2026-11-01T18:28:49+08:00","備註":"已實讀明列稿源Boomray Pharmaceuticals Co., Ltd.的PRNewswire原稿全文。USD 900m包含未分拆首付及開發、監管、銷售里程碑。公司整體clinical-stage不代表本資產進臨床。官網About全文開啟逾時，官方搜尋快照列蘇州總部，原稿亦以蘇州中國發稿。"},{"交易ID":"ASIA-2026-53d62df8d895","公告日期":"2026-09-16","授權方_中文名":"上海詩健生物科技有限公司","授權方_英文名":"Shanghai Escugen Biotechnology Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"","被授權方_英文名":"Sovran Bio, Inc.","被授權方_國家":"美國","資產名稱與代號":"未披露代號之泛腫瘤雙特異性ADC共同開發計畫","藥物類型":"雙特異性抗體藥物複合體（ADC）","標的或機制":"","最高開發階段_公告當時":"","授權地區範圍":"","交易類型":"藥物共同開發／平台合作","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"","來源網址1":"https://www.sovranbio.com/data/Escugen%20and%20Sovran%20Co-Development%20Announcement.pdf","來源網址2":"https://escugen.com.cn/en/news/100.html","來源日期":"2026-09-16","查核時間":"2026-11-01T18:28:49+08:00","備註":"新共同開發協議延伸既有合作，只計9月新協議，不重計2025合作。確切靶點組合、臨床期別、地域權利分配及經濟條款未披露，不以其他ADC或公司階段補填。原稿核雙方為上海Escugen及Woodinville, Washington之Sovran。屬允許之藥物平台共同開發，未宣稱已披露獨家license-out。"},{"交易ID":"ASIA-2026-a488e95181b5","公告日期":"2026-09-03","授權方_中文名":"和黃醫藥集團旗下HUTCHMED Limited","授權方_英文名":"HUTCHMED Limited (subsidiary of HUTCHMED (China) Limited)","授權方_國家":"中國（香港）","授權方_上市代號":"0013.HK; HCM.Nasdaq; HCM.AIM（母公司）","被授權方_英文名":"GlaxoSmithKline Intellectual Property (No. 4) Limited (GSK subsidiary)","被授權方_國家":"英國","資產名稱與代號":"HMPL-A830（附另一項較早期ATTC資產優先議約權）","藥物類型":"抗體標靶治療複合體（ATTC）：KRAS抑制劑與抗EGFR抗體連接","標的或機制":"KRAS / EGFR","最高開發階段_公告當時":"臨床前；全球一期預計2026下半年開始","授權地區範圍":"全球，排除中國大陸、香港、澳門及台灣","交易類型":"獨家開發及藥物授權，附另一資產優先議約權","首付款_美元":"110000000","近期里程碑_美元":"","交易總額上限_美元":"1295000000","權利金描述":"年度淨銷售額分級權利金；費率未披露","來源網址1":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000057/hcm-20260903xex99d1.htm","來源網址2":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426008359/a6888u.htm","來源日期":"2026-09-03","查核時間":"2026-11-01T18:28:49+08:00","備註":"實際授權方HUTCHMED Limited，代號屬母公司，母公司主營執行辦公室香港。總額含首付，另最高USD 1.185bn開發、監管及商業里程碑。首付於交割支付，公告時仍待交割條件。保留大中華權利。依9/3時點不倒填後續披露一期進度；優先議約權不拆筆。GSK集團principal executive office倫敦；另核英國公司登記之實際受權方。"},{"交易ID":"ASIA-2026-dbb169015879","公告日期":"2026-09-02","授權方_中文名":"Alteogen","授權方_英文名":"Alteogen Inc.","授權方_國家":"韓國","授權方_上市代號":"KOSDAQ:196170","被授權方_英文名":"Novartis","被授權方_國家":"瑞士","資產名稱與代號":"ALT-B4 (berahyaluronidase alfa) / Hybrozyme-enabled SC formulations of multiple undisclosed Novartis products","藥物類型":"重組人類玻尿酸酶皮下給藥平台","標的或機制":"Hyaluronan (delivery substrate); therapeutic targets undisclosed","最高開發階段_公告當時":"","授權地區範圍":"","交易類型":"Option and license agreement","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"3223000000","權利金描述":"Net-sales royalties; rates undisclosed","來源網址1":"https://en.prnasia.com/releases/global/alteogen-enters-option-and-license-agreement-with-novartis-for-development-and-commercialization-of-hybrozyme-enabled-subcutaneous-products-546224.shtml","來源網址2":"https://www.sec.gov/Archives/edgar/data/1114448/000111444826000004/nvs-20251231.htm","來源日期":"2026-09-02","查核時間":"2026-11-01T18:28:49+08:00","備註":"全部選擇權行使及全部里程碑達成才可能達US$3,223m；非已收首付。原稿將選擇權行使費、開發/商業里程碑與銷售權利金併述，未拆各額及權利金是否另計；總額僅保留條件式公告口徑，不再加總權利金。產品、階段、地域未公開。按Novartis瑞士Basel總部核國別，原稿未指名契約子公司。"},{"交易ID":"ASIA-2026-bc2c6a361c5b","公告日期":"2026-09-01","授權方_中文名":"先聲藥業集團有限公司／先聲再明","授權方_英文名":"Simcere Pharmaceutical Group Limited / Simcere Zaiming","授權方_國家":"中國","授權方_上市代號":"2096.HK（集團）","被授權方_英文名":"F. Hoffmann-La Roche Ltd","被授權方_國家":"瑞士","資產名稱與代號":"SIM0660","藥物類型":"三特異性T細胞衔接抗體（TCE）","標的或機制":"CD79a / CD19 / CD3","最高開發階段_公告當時":"","授權地區範圍":"全球","交易類型":"獨家藥物權利授權","首付款_美元":"75000000","近期里程碑_美元":"","交易總額上限_美元":"1530000000","權利金描述":"未來淨銷售額最高至雙位數之分級權利金","來源網址1":"https://en.simcere.com/news/detail.aspx?mtt=1609","來源網址2":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0901/2026090102901.pdf","來源日期":"2026-09-01","查核時間":"2026-11-01T18:28:49+08:00","備註":"公司原稿最高USD 1.530bn含75m首付；HKEX列其餘最高USD 1.455bn里程碑。公告未明載臨床期別，留空。官網以先聲再明品牌公告，HKEX以香港設立Group簽約，精確簽約子公司未披露；未把美國Simcere Zaiming Inc.擅當授權方。2026中報核集團南京總部。Roche取得全球獨家開發、生產及商業化權。"},{"交易ID":"ASIA-2026-b915988714b3","公告日期":"2026-08-28","授權方_中文名":"映恩生物","授權方_英文名":"DUALITYBIO Inc. (DualityBio)","授權方_國家":"中國","授權方_上市代號":"09606.HK","被授權方_英文名":"Genentech, Inc.","被授權方_國家":"美國","資產名稱與代號":"DUPAC platform-derived oncology ADC collaboration programs","藥物類型":"Antibody-drug conjugate platform","標的或機制":"","最高開發階段_公告當時":"Discovery collaboration; individual program clinical phases not disclosed","授權地區範圍":"Worldwide exclusive license to collaboration ADCs","交易類型":"Research collaboration and exclusive license","首付款_美元":"45000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"Tiered royalties on annual net sales; rates undisclosed","來源網址1":"https://en.dualitybiologics.com/news/614.html","來源網址2":"https://www.gene.com/contact-us/visit-us","來源日期":"2026-08-28","查核時間":"2026-11-01T18:28:49+08:00","備註":"上海公告；Genentech國別按其美國總部，未以瑞士母公司Roche替代。靶點由Genentech指定但未公開。首付45m；潛在開發、監管及商業里程碑合計為逾1,000m，屬下限敘述而非精確上限，故total_cap留空。未將DualityBio其他已入臨床的ADC當成此次新合作資產的階段。"},{"交易ID":"ASIA-2026-0c1e5290eb1a","公告日期":"2026-08-25","授權方_中文名":"海思科醫藥集團股份有限公司","授權方_英文名":"Haisco Pharmaceutical Group Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"002653.SZ","被授權方_英文名":"Sentivera Therapeutics","被授權方_國家":"美國","資產名稱與代號":"Undisclosed oral small-molecule autoimmune / type 2 inflammation program","藥物類型":"Oral small molecule","標的或機制":"","最高開發階段_公告當時":"Preclinical; China IND approved in August 2026, no human clinical phase disclosed","授權地區範圍":"Worldwide excluding mainland China, Hong Kong, Macao and Taiwan","交易類型":"Exclusive license with NewCo equity consideration","首付款_美元":"40000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"Tiered royalties; website states up to 10%, issued release states mid single-digit to low double-digit; potential sublicensing revenue share","來源網址1":"https://www.haisco.com/en/news/1831.html","來源網址2":"https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-new-us-venture-founded-by-population-health-partners-and-arch-venture-partners-302859307.html","來源日期":"2026-08-25","查核時間":"2026-11-01T18:28:49+08:00","備註":"75.89m總前期對價拆為40m現金及估值35.89m的Sentivera 17.5%股權；股權未填入現金首付。另有最高1,460m里程碑，headline僅稱逾1.5b且包含股權，故不填精確total_cap。公司官網原稿標臨床前且已獲中國臨床試驗許可，不能推為已啟動一期。公司原稿確認Sentivera為美國Delaware公司；8/25為公司對外發布日，官網清單8/26為轉載日期。"},{"交易ID":"ASIA-2026-2571bb5d80f6","公告日期":"2026-08-18","授權方_中文名":"田邊製藥","授權方_英文名":"Tanabe Pharma Corporation","授權方_國家":"日本","授權方_上市代號":"","被授權方_英文名":"LEO Pharma A/S","被授權方_國家":"丹麥","資產名稱與代號":"Dersimelagon / MT-7117","藥物類型":"口服非胜肽小分子","標的或機制":"MC1R（melanocortin-1 receptor）致效劑","最高開發階段_公告當時":"Phase 3 INSPIRE 已公布正向結果；2026-06-30 向 FDA 提交 NDA，公告當時尚未記為受理","授權地區範圍":"全球開發與商業化權","交易類型":"全球藥物資產權利轉讓","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"分級銷售權利金；級距未披露","來源網址1":"https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-enters-into-agreement-with-leo-pharma-for-mt-7117-for-epp-and-xlp","來源網址2":"https://leo-pharma.com/media-center/leo-pharma-delivers-10-revenue-growth-at-cer-and-strengthens-late-stage-pipeline/","來源日期":"2026-08-18","查核時間":"2026-11-01T18:28:49+08:00","備註":"原稿明列 Tanabe 大阪總部及 LEO Pharma 丹麥 Ballerup 總部。治療 EPP 與 XLP 光敏感。USD 435,000,000 是首付加近期里程碑的合併上限，未披露拆分，另有未量化後續里程碑及權利金，因此三個金額欄均留空，不能把 435m 全算首付或全部交易上限。2026-09-18 交割及 NDA 受理屬同協議後續事件，未拆成另一筆。"},{"交易ID":"ASIA-2026-46a9e18971ef","公告日期":"2026-08-03","授權方_中文名":"江蘇康寧傑瑞生物製藥有限公司（康寧傑瑞）","授權方_英文名":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"9966.HK (parent: Alphamab Oncology)","被授權方_英文名":"Pathos AI, Inc.","被授權方_國家":"美國","資產名稱與代號":"JSKN016","藥物類型":"Bispecific antibody-drug conjugate","標的或機制":"TROP2 / HER3","最高開發階段_公告當時":"Phase III ongoing in triple-negative breast cancer; earlier trials in other tumors","授權地區範圍":"Worldwide excluding mainland China, Hong Kong, Macau and Taiwan","交易類型":"Exclusive license","首付款_美元":"125000000","近期里程碑_美元":"","交易總額上限_美元":"2093000000","權利金描述":"High single-digit to low double-digit tiered percentages of licensed-territory net sales","來源網址1":"https://www.pathos.com/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2-her3-bispecific-adc","來源網址2":"https://www.alphamabonc.com/html/news/2931.html","來源日期":"2026-08-03","查核時間":"2026-11-01T18:28:49+08:00","備註":"採Pathos原稿New York 8/3 dateline；Pathos頁面及康寧傑瑞中文稿刊登8/4，合併為同一協議。中文公司原稿明稱首付與里程碑總額最高2,093m，不能再加125m。另有可由康寧傑瑞自行選擇行使、認購總價62.5m的Pathos認股權證，屬授權方可能對外投資，非收到的首付或里程碑。中文原稿核對Pathos為Delaware註冊、New York總部。"},{"交易ID":"ASIA-2026-8b7c9b63dada","公告日期":"2026-07-14","授權方_中文名":"上海翰森生物醫藥科技有限公司（翰森製藥）","授權方_英文名":"Shanghai Hansoh Biomedical Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"03692.HK (parent: Hansoh Pharmaceutical Group)","被授權方_英文名":"Avere Therapeutics, Inc.","被授權方_國家":"美國","資產名稱與代號":"HS-20118 / AVR-001","藥物類型":"Oral peptide","標的或機制":"IL-23 receptor","最高開發階段_公告當時":"Phase Ib psoriasis data available; Phase II planned","授權地區範圍":"Worldwide excluding mainland China, Hong Kong, Macao and Taiwan","交易類型":"Exclusive license; concurrent strategic equity investment is separate","首付款_美元":"90000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"Mid single-digit to low double-digit tiered royalties","來源網址1":"https://www.hansoh.cn/news/news-detail-514051.htm","來源網址2":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926098412/nxtc-20260630xs4.htm","來源日期":"2026-07-14","查核時間":"2026-11-01T18:28:49+08:00","備註":"公司7/14公開稿稱120m首付及最高2,180m里程碑，未直接披露整體總額，不自行相加，total_cap留空。8/18 SEC S-4進一步拆為90m簽約現金、30m合格反向合併完成條件款；本表首付欄記立即現金90m，30m屬遞延／條件式首付，非近期里程碑，僅於此保留條件。SEC另列授予翰森Seed股公允價值約67m，未混入現金欄。SEC表示開發里程碑280m按產品計，不能解讀為多產品無條件總封頂。Avere融資／反向合併金額另案排除。公告日非SEC揭露的6月簽約日；Avere為Delaware公司、Burlington MA總部。"},{"交易ID":"ASIA-2026-85ed4076ff2c","公告日期":"2026-07-14","授權方_中文名":"信達生物製藥（蘇州）有限公司及Fortvita Biologics (USA), Inc.","授權方_英文名":"Innovent Biologics (Suzhou) Co., Ltd.; Fortvita Biologics (USA), Inc.","授權方_國家":"中國","授權方_上市代號":"01801.HK (parent: Innovent Biologics)","被授權方_英文名":"Spero Therapeutics, Inc.","被授權方_國家":"美國","資產名稱與代號":"SP001 / IBI355 and related anti-CD40L compounds","藥物類型":"Monoclonal antibody","標的或機制":"CD40L","最高開發階段_公告當時":"Phase Ib evaluated; Phase II-ready, Phase II planned for 2027","授權地區範圍":"Worldwide excluding mainland China, Taiwan, Hong Kong and Macau","交易類型":"Exclusive license","首付款_美元":"35000000","近期里程碑_美元":"","交易總額上限_美元":"1100000000","權利金描述":"Tiered royalties on net sales; rates undisclosed in joint announcement","來源網址1":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm","來源網址2":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658dex991.htm","來源日期":"2026-07-14","查核時間":"2026-11-01T18:28:49+08:00","備註":"7/14共同稿將總額列約1.1b；同日8-K拆明35m首付及約1.05b後續里程碑，total_cap保留共同稿四捨五入近似值，非精確上限。7/8為簽約日，7/14為公開公告日。中國國別按信達蘇州營運集團；8-K法定共同授權方另有美國Fortvita，已並列。Phase 2-ready不等於二期已啟動；融資105m與此授權金額無關，未混入。Spero SEC封面核對Delaware註冊及Cambridge MA總部。"},{"交易ID":"ASIA-2026-4789e7c72503","公告日期":"2026-07-14","授權方_中文名":"迪哲（江蘇）醫藥股份有限公司","授權方_英文名":"Dizal Pharmaceutical Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"688192.SH","被授權方_英文名":"AstraZeneca","被授權方_國家":"英國","資產名稱與代號":"Zegfrovy / sunvozertinib","藥物類型":"Oral small molecule","標的或機制":"EGFR, including exon 20 insertion mutations","最高開發階段_公告當時":"Approved in United States and China for previously treated EGFR exon 20 insertion NSCLC","授權地區範圍":"Worldwide development and commercialization rights","交易類型":"Exclusive global license","首付款_美元":"600000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"Tiered royalties on global sales; rates undisclosed","來源網址1":"https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-licenses-novel-egfr-inhibitor.html","來源網址2":"https://star.sse.com.cn/star/market/stocklist/info/company/index.shtml?COMPANY_CODE=688192","來源日期":"2026-07-14","查核時間":"2026-11-01T18:28:49+08:00","備註":"公告披露600m美元首付及最高900m美元開發、監管、銷售里程碑，另有全球銷售分級權利金；未直接披露整體總額，不自行相加，total_cap留空。公告當時已有美中核准，不能僅記Phase III；一線適應症進展不等於已獲該適應症核准。公告稱預計H2交割，非當日完成。AZ原稿明列Cambridge UK；上交所核對迪哲法定名稱、代碼及中國地址。9月完成公告不重複計為新協議。source_url1正規化為同一AZ原稿的正式乾淨URL；原研究存錄之.htmlon-deal尾碼與AZ／Cision同稿已核對，未另計交易。"},{"交易ID":"ASIA-2026-c0e5630afbb9","公告日期":"2026-07-08","授權方_中文名":"正大天晴藥業集團股份有限公司（中國生物製藥）","授權方_英文名":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"01177.HK (parent: Sino Biopharmaceutical / SBP Group)","被授權方_英文名":"AstraZeneca","被授權方_國家":"英國","資產名稱與代號":"TQC3721; certain future development programs","藥物類型":"Inhaled small molecule","標的或機制":"PDE3 / PDE4","最高開發階段_公告當時":"Phase III in China for nebulized formulation in COPD; dry-powder formulation Phase II","授權地區範圍":"TQC3721 outside China; certain future development programs worldwide","交易類型":"Exclusive license","首付款_美元":"200000000","近期里程碑_美元":"","交易總額上限_美元":"1900000000","權利金描述":"Tiered royalties up to double-digit percentages of annual net sales","來源網址1":"https://www.en.sbpgroup.com/userfiles/files/Anno-Equity/E26075455-Sino%20Bio-PA.pdf","來源網址2":"https://www.sbpgroup.com/news-center/dynamic/25082.html","來源日期":"2026-07-08","查核時間":"2026-11-01T18:28:49+08:00","備註":"原公告英文將200m首付與里程碑合寫totalling up to1.9b；8/20公司中文業績原稿明確稱交易總額最高1.9b，故不能加成2.1b。以公告日原文核對最高Phase III，並保留不同劑型的Phase II。公告仍有交割條件；未把授權當成藥物核准。授權方為中國CTTQ，股票碼屬母公司；AZ國別用其Cambridge UK總部。"},{"交易ID":"ASIA-2026-03096fe86b73","公告日期":"2026-07-02","授權方_中文名":"石藥集團有限公司","授權方_英文名":"CSPC Pharmaceutical Group Limited","授權方_國家":"中國","授權方_上市代號":"01093.HK","被授權方_英文名":"AstraZeneca","被授權方_國家":"英國","資產名稱與代號":"Two renal-disease siRNA target programs","藥物類型":"siRNA drug discovery platform / small nucleic acid therapeutics","標的或機制":"","最高開發階段_公告當時":"Discovery / preclinical candidate development","授權地區範圍":"Option for worldwide or ex-China exclusive rights, depending on program; CSPC retains China rights to one candidate","交易類型":"Research collaboration, option and license agreement","首付款_美元":"30000000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"Potential single-digit royalties on annual net sales","來源網址1":"https://doc.irasia.com/listco/hk/cspc/announcement/a260702.pdf","來源網址2":"https://www.cspc.com.hk/en/ir/announcements.php","來源日期":"2026-07-02","查核時間":"2026-11-01T18:28:49+08:00","備註":"公告披露30m美元首付、最高540m美元開發里程碑及最高1,200m美元銷售里程碑，另有潛在權利金；未直接披露整體總額，不自行相加，total_cap留空。兩項靶點未揭露，屬一份多資產協議，未拆兩筆。權利為可選擇取得，不能當成全部選擇權已行使。中國國別指中國營運石藥集團，原公告註法律主體於香港註冊。8/12首付到帳公告屬同協議，不重複入列；未混入另份AZ肽類或2025合作。"},{"交易ID":"ASIA-2026-b188fd4b16e2","公告日期":"2026-06-02","授權方_中文名":"雲頂新耀","授權方_英文名":"Everest Medicines","授權方_國家":"中國","授權方_上市代號":"01952.HK","被授權方_英文名":"Travere Therapeutics, Inc.","被授權方_國家":"美國","資產名稱與代號":"Civorebrutinib / EVER001","藥物類型":"Oral small molecule","標的或機制":"BTK","最高開發階段_公告當時":"Phase I/II proof-of-concept in primary membranous nephropathy","授權地區範圍":"All markets outside China and certain countries in East and Southeast Asia","交易類型":"Exclusive license and collaboration","首付款_美元":"112500000","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"High single-digit to double-digit tiered royalties on licensed-territory sales","來源網址1":"https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Enters-Into-Exclusive-Licensing-Agreement-with-Everest-Medicines-for-Civorebrutinib-a-Potential-Best-in-Class-BTK-Inhibitor-for-Rare-Kidney-Diseases/default.aspx","來源網址2":"https://www.everestmedicines.com/about-us/contact-us","來源日期":"2026-06-02","查核時間":"2026-11-01T18:28:49+08:00","備註":"原稿披露112.5m美元首付及最高約1,030m美元後續現金里程碑，另有分級銷售權利金；未直接披露整體總額，不自行相加，total_cap留空，亦不把近似分項加成精確總額。里程碑涵蓋最多五適應症，不拆五筆。6/2原稿僅稱Phase1/2，不以8月快照的後續basket trial回填公告時最高階段。原稿未逐國列出保留的東亞／東南亞地區，territory保持原文範圍。Everest官方列上海Corporate Headquarters；Travere原稿San Diego確認美國。"},{"交易ID":"ASIA-2026-e3a7ba3b5de1","公告日期":"2026-06-01","授權方_中文名":"Oscotec","授權方_英文名":"Oscotec Inc.","授權方_國家":"韓國","授權方_上市代號":"KOSDAQ:039200","被授權方_英文名":"Agios Pharmaceuticals, Inc.","被授權方_國家":"美國","資產名稱與代號":"Cevidoplenib (SKI-O-703)","藥物類型":"口服小分子激酶抑制劑","標的或機制":"SYK","最高開發階段_公告當時":"Phase 2 completed (ITP); Phase 3 planned, not initiated","授權地區範圍":"Worldwide; Oscotec South Korea opt-in after Phase 3 results","交易類型":"Exclusive global license","首付款_美元":"25000000","近期里程碑_美元":"","交易總額上限_美元":"665000000","權利金描述":"High-single-digit to mid-teen net-sales royalties","來源網址1":"https://investor.agios.com/news-releases/news-release-details/agios-enters-exclusive-global-license-agreement-oscotec-develop","來源網址2":"https://oscotec.com/archives/394656","來源日期":"2026-06-01","查核時間":"2026-11-01T18:28:49+08:00","備註":"Agios 6/1原稿：US$25m首付、最高US$140m開發/監管里程碑，另有商業里程碑；US$165m不是完整上限。Oscotec 6/2原始股東函列US$665m潛在總額。共同開發者Genosco分配25%、Oscotec75%，不另拆交易。公告當時三期預計2028上半年。Agios原稿明列總部Cambridge, Massachusetts。"},{"交易ID":"ASIA-2026-54e85abb9ba4","公告日期":"2026-06-01","授權方_中文名":"海思科醫藥科技（拉薩）有限公司（海思科）","授權方_英文名":"Haisco Pharmaceutical Technology (Lhasa) Co., Ltd.","授權方_國家":"中國","授權方_上市代號":"002653.SZ (parent: Haisco Pharmaceutical Group)","被授權方_英文名":"Eli Lilly and Company","被授權方_國家":"美國","資產名稱與代號":"Up to five undisclosed innovative small-molecule target programs","藥物類型":"Small-molecule discovery platform / programs","標的或機制":"","最高開發階段_公告當時":"Discovery / early research collaboration; no clinical phase disclosed","授權地區範圍":"Worldwide exclusive rights or worldwide excluding mainland China, Hong Kong, Macao and Taiwan, depending on program","交易類型":"License and research collaboration","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"3054000000","權利金描述":"Tiered royalties on future product net sales; rates undisclosed in company original","來源網址1":"https://www.haisco.com/news/18.html","來源網址2":"","來源日期":"2026-06-01","查核時間":"2026-11-01T18:28:49+08:00","備註":"公司6/1原稿指5/29簽約；用公開公告日6/1。最多87m為首付款和近期付款合計且依項目提名/候選確認等條件，不可全部列upfront，兩欄均留空。另最高2,967m後續里程碑；87m+2,967m=3,054m，與原稿標題最高30.54億美元一致。最多五項為一份協議；未揭露靶點或臨床分期，無法推為臨床管線。原稿明列拉薩全資子公司及美國Eli Lilly。"},{"交易ID":"ASIA-2026-bc1534c230ab","公告日期":"2026-04-01","授權方_中文名":"第一三共","授權方_英文名":"Daiichi Sankyo Company, Limited","授權方_國家":"日本","授權方_上市代號":"TSE:4568","被授權方_英文名":"Nuvation Bio Inc.","被授權方_國家":"美國","資產名稱與代號":"Safusidenib / DS-1001","藥物類型":"口服、可穿透腦部的小分子","標的或機制":"突變型 IDH1","最高開發階段_公告當時":"Phase 3 SIGMA 進行中；IDH1 突變型星狀細胞瘤","授權地區範圍":"本次追加日本權利；修約後 Nuvation 持有全球獨家開發及商業化權","交易類型":"既有獨家藥物授權修約／追加日本權利","首付款_美元":"","近期里程碑_美元":"","交易總額上限_美元":"","權利金描述":"","來源網址1":"https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Announces-Acquisition-of-Japan-Rights-to-Safusidenib-from-Daiichi-Sankyo/default.aspx","來源網址2":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526336646/nuvb-ex10_1.htm","來源日期":"2026-04-01","查核時間":"2026-11-01T18:28:49+08:00","備註":"本筆是 2026 年新增日本權利的修約，不把 2020 年日本以外原始協議重算為全新全球授權。原公告未拆披露本次追加權利的對價，金額及權利金留空。SEC 合約序文明列授權方日本公司／東京主要營業處，以及受讓方美國 Delaware 公司／紐約辦公室。SEC 合約日期是生效日 2026-04-01，並非將其申報日期推定為同日。"}],"sources":[{"file":"dots_queue/done/亞洲出海交易_批次01.csv","sha256":"65d67b87a13a1117c72429c71b7750e8caaa1b673c64d3716a7aafa8c9eb1eea","rows":30}],"duplicates_removed":0,"stats":{"count":30,"upfront_usd":3247500000,"total_cap_usd":20965000000,"upfront_disclosed":18,"cap_disclosed":12,"earliest":"2026-04-01","latest":"2026-10-29","types":[["Small molecules",10],["ADC / conjugates",5],["Antibodies",3],["Enzymes / proteins",3],["Other / unspecified",3],["Delivery platforms",2],["RNA therapeutics",2],["Peptides",1],["Radiopharmaceuticals",1]],"countries":[["China",24],["Japan",3],["South Korea",3]]}}